New Single-Molecule Technique Reads Intact Tau Proteins at Unprecedented Scale

Scientists have unveiled a powerful new method that allows researchers to measure intact protein forms, known as proteoforms, one molecule at a time and on a scale never before possible. The technique, called Iterative Mapping of proteoforms, was demonstrated on tau, the misbehaving protein at the center of Alzheimer’s disease and a family of devastating neurodegenerative conditions collectively known as tauopathies. By quantifying tau proteoform groups across control samples of known composition, model systems used in tauopathy research, and human-derived brain tissue samples, the approach opens a window into a layer of molecular biology that conventional tools have long struggled to capture.

Proteins are not static entities. After they are translated from messenger RNA, they undergo a dizzying array of chemical modifications: phosphate groups are added and removed, the protein backbone is clipped by proteases, small protein tags such as ubiquitin are attached, and amino acids can be chemically altered in dozens of other ways. Each unique combination of modifications and sequence variants constitutes a distinct proteoform. The trouble is that two proteoforms of the same protein can behave in radically different ways inside a cell, one folding into a harmless shape and another seeding the toxic aggregates that kill neurons. Standard proteomics methods, which typically chop proteins into small peptides before identifying them, lose the connectivity information that reveals which modifications coexisted on the same original molecule. As a result, the proteoform landscape of even a well-studied protein like tau has remained only partially charted.

Iterative Mapping of proteoforms tackles this problem by interrogating individual protein molecules directly, preserving the integrity of each proteoform throughout the measurement. The core idea is to perform repeated cycles of imaging-based readout on single immobilized molecules, building up a pattern of signals that serves as a molecular fingerprint. Because each molecule is observed on its own, the resulting data reflect genuine single-molecule heterogeneity rather than population averages. This matters enormously for tau, where rare proteoforms may be the biologically decisive species. A modification present on only one percent of tau molecules could be invisible to bulk measurements, yet a small pool of aberrantly modified molecules might be sufficient to nucleate the pathological aggregates that spread through the brain in Alzheimer’s disease.

The scale of the new approach is what sets it apart. Earlier single-molecule protein characterization methods, while conceptually elegant, were limited in throughput, making it impractical to survey the full diversity of proteoforms in complex biological samples. Iterative Mapping achieves large-scale measurement by combining highly parallel detection with an iterative readout strategy, allowing millions of individual molecules to be characterized in a single experiment. The researchers validated the technique using control samples of known composition, a critical step that established the method’s accuracy in quantifying predefined proteoform groups. Only after demonstrating that the technique could correctly identify and count proteoforms in mixtures of known makeup did the team apply it to more complex and clinically relevant material.

Tau is an unusually challenging target for such an analysis. In the human brain, the MAPT gene produces six major isoforms of tau through alternative splicing, differing in the number of microtubule-binding repeats and N-terminal inserts. On top of this isoform diversity, tau carries an enormous number of possible phosphorylation sites, with dozens of serine, threonine, and tyrosine residues that can be modified individually or in combination. The phosphorylation state of tau governs its normal function in stabilizing microtubules, the structural scaffolds of neurons, but hyperphosphorylation promotes tau’s detachment from microtubules, its misfolding, and ultimately its aggregation into the paired helical filaments that compose neurofibrillary tangles. Because the biological consequences of phosphorylation depend on which sites are modified together on the same molecule, knowing the total amount of tau phosphorylation in a sample is far less informative than knowing the actual distribution of proteoforms.

The demonstration in model systems used in tauopathy research provides a bridge between controlled validation experiments and human tissue. Cell and animal models of tauopathy are workhorses of the field, used to test hypotheses about how tau becomes pathological and to screen candidate therapies. Applying Iterative Mapping to these systems allows researchers to characterize how the tau proteoform landscape shifts as disease-like states develop, and to compare the proteoform signatures of different models against one another. Such comparisons could help resolve a persistent problem in the field: different model systems recapitulate different aspects of tau pathology, and it has been difficult to know which models most faithfully reflect the human disease. A quantitative, single-molecule proteoform census offers a new common currency for making those comparisons.

The most striking application, however, is the analysis of human-derived brain tissue samples. Post-mortem brain tissue from individuals with Alzheimer’s disease and related tauopathies is a precious and technically difficult resource, often available in limited quantities and frequently affected by post-mortem delays and variable tissue quality. Demonstrating that Iterative Mapping can extract meaningful proteoform quantification from such material establishes the method’s readiness for real-world translational research. The ability to profile tau proteoform groups directly in human brain tissue means that hypotheses generated in models can now be tested against the actual molecular substrate of disease, and that proteoform patterns associated with specific diagnoses, disease stages, or clinical outcomes can be systematically searched for.

The implications for drug development could be substantial. A growing number of therapeutic strategies target tau directly, including antisense oligonucleotides designed to reduce tau production, immunotherapies intended to clear pathological tau species, and small molecules aimed at inhibiting the kinases that phosphorylate tau. Each of these approaches would benefit from a measurement technology that can report precisely which proteoforms are reduced or altered following treatment. Bulk phosphorylation assays can indicate that total tau phosphorylation has decreased, but they cannot reveal whether the specific proteoform groups thought to drive toxicity have been affected. Single-molecule proteoform quantification provides exactly that granularity, potentially enabling biomarker-guided clinical trials in which molecular responses are monitored at the level of individual protein species.

Beyond tau, the demonstration establishes a general template for large-scale single-molecule proteoform analysis that could be extended to other proteins of biomedical importance. Alpha-synuclein in Parkinson’s disease, huntingtin in Huntington’s disease, TDP-43 in amyotrophic lateral sclerosis, and amyloid precursor protein in Alzheimer’s disease all share the same basic challenge: their pathological behavior depends on proteoform-level details that bulk methods obscure. If Iterative Mapping can be adapted to these targets, the technology could catalyze a broader shift in proteomics toward intact-protein, single-molecule measurement, complementing the peptide-centric workflows that have dominated the field for decades. The convergence of single-molecule imaging, iterative biochemical readout, and computational analysis reflected in this work suggests that the long-sought goal of routinely reading complete proteoforms is moving from aspiration toward practice.

Challenges remain before such methods become routine in laboratories and clinics. Sample preparation for single-molecule analysis must preserve labile modifications, the computational pipelines for interpreting iterative readout patterns must be robust across diverse sample types, and the proteoform groups quantified today represent a subset of the full molecular diversity that likely exists in brain tissue. Nevertheless, the demonstration that large-scale, single-molecule proteoform measurement is achievable, validated against known controls, and applicable to human tissue marks a genuine advance. For a protein like tau, whose transformation from a neuronal workhorse into a killer aggregate has puzzled researchers for decades, the ability to count and classify its molecular forms one molecule at a time may finally provide the resolution needed to understand, and ultimately interrupt, the progression of tauopathy.

Subject of Research: Large-scale single-molecule measurement of intact tau proteoforms using Iterative Mapping

Article Title: Large-scale single-molecule analysis of tau proteoforms

Article References: Joly, J., Budamagunta, V., Zhang, Z., Nortman, B., Jouzi, M., Bhatnagar, R., Egertson, J. D., Flaster, M. E., Grothe, R., Guha, S., Kaneshige, K., McVey, K., Nelson, N., Perera, R. T., Tan, S. J., Trinh, T., Arnott, D., Lipka, J., Pandya, N. J., … Mallick, P. (2026). Large-scale single-molecule analysis of tau proteoforms. Nature Methods, 23(9), 1786-1797. https://doi.org/10.1038/s41592-026-03188-6

Image Credits: AI Generated

DOI: 10.1038/s41592-026-03188-6

Keywords: tau, proteoforms, single-molecule analysis, Iterative Mapping, tauopathy, Alzheimer's disease, phosphorylation, proteomics, neurodegeneration, brain tissue, biomarkers, drug development